Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.

British journal of haematology - 1 Dec 2024

Boussi Leora, Biswas Jeetayu, Abdel-Wahab Omar, Stein Eytan

Abstract excerpt

In recent years, large-scale sequencing efforts have identified targetable driver mutations in haematopoietic stem cells. These efforts have led to the development and approval of nine novel agents for relapsed or refractory acute myelogenous leukaemia (R/R AML). However, despite an expansion in targeted therapies, achieving a durable remission in AML and high-risk myelodysplastic syndrome (HR-MDS) remains a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Leukemia, Myeloid, Acute
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to RNA Splicing

Share to RNA Splicing Factors

Share to Spliceosomes

Source

Identifiers

PMID: 39406457
DOI: 10.1111/bjh.19826

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.PMID 39406457Read ↗

RNA splicing as a therapeutic target in myelodysplastic syndromes.Semantic proximity Read ↗

Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.Semantic proximity Read ↗

Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.Semantic proximity Read ↗

Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical FeaturesSemantic proximity Read ↗

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.Semantic proximity Read ↗

[RNA splicing dysregulation in hematological malignancies].Semantic proximity Read ↗

Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia.Semantic proximity Read ↗

[Hematological malignancies driven by aberrant splicing].Semantic proximity Read ↗

Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.Semantic proximity Read ↗

RNA splicing factors in normal hematopoiesis and hematologic malignancies: novel therapeutic targets and strategies.Semantic proximity Read ↗

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.Semantic proximity Read ↗

Complex landscape of alternative splicing in myeloid neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.